11. April 2024 | Corporate News

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

  • Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio
  • Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infections in Mexico
  • Further value maximization and revenue potential for Carragelose asset

 

The full press release is available as download here: 

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
(61 KB)